By Chris Wack

 

Alpine Immune Sciences Inc. said it is in a clinical trial collaboration and supply agreement with Merck.

The company said the collaboration will evaluate the safety and efficacy of Alpine's ALPN-202, a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor, in combination with Merck's anti-PD-1 therapy Keytruda pembrolizumab.

The clinical trial began dosing study participants in June.

Keytruda is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.

Alpine shares were up 9%, to $9.89, in premarket trading.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

June 30, 2021 08:30 ET (12:30 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Merck Charts.